Prospective study of intensity-modulated radiation therapy using standard radiation dose for high-grade glioma

Prospective study of intensity-modulated radiation therapy using standard radiation dose for high-grade glioma - IMRT using standard radiation dose for HGG

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022502

Enrollment

Registered

2016-05-27

Start date

2016-05-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High-grade glioma

Interventions

The prescribed dose of IMRT is 60 Gy in 30 fractions over 6 weeks (2 Gy per fraction, five fractions per week). The chemotherapy regimens are not regulated.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically proven high-grade glioma 2. No tumor recognized in the brainstem and optic nerve on preoperative MRI 3. Planning target volume (irradiated 60Gy) is less than 1/3 of the brain volume 4. Aged 20 to 75 years old 5. ECOG performance status of 0,1 or 3 due to neurological signs caused by the tumor 6. Written informed consent

Exclusion criteria

Exclusion criteria: 1. No prior radiation therapy for intracranial disease 2. Prior treatment for high-grade glioma 3. Women during pregnancy, possible pregnancy, or breast-feeding, patient who wish pregnancy 4. Psychiatric disease 5. Inappropriate patients for this study judged by physicians

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Progression-free survival, Completion rate of IMRT, Grade 3 or more non-hematological toxicity evaluated every 12 months	—

Countries

Japan

Contacts

Public ContactShigeo Takahashi

Kagawa University Hospital Department of Radiation Oncology

takahashi.shigeo@kagawa-u.ac.jp087-898-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026